stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) EBITDA
HUTCHMED (China) Limited Sponsored ADR's EBITDA for fiscal 2025 was −$25.9M, compared with −$31.4M in fiscal 2024. Over the past ten years it has ranged from −$399.0M (fiscal 2022) to $26.6M (fiscal 2023); the current reading is higher than 82% of that period. HUTCHMED (China) Limited Sponsored ADR ranks 80th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$25.9M | — |
| FY2024 | −$31.4M | — |
| FY2023 | $26.6M | — |
| FY2022 | −$399.0M | — |
| FY2021 | −$321.1M | — |
| FY2020 | −$190.6M | — |
| FY2019 | −$141.4M | — |
| FY2018 | −$89.1M | — |
| FY2017 | −$50.8M | — |
| FY2016 | −$44.4M | — |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| ANIP ANI Pharmaceuticals, Inc. compare | $236.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $52.9M |
| RGC Regencell Bioscience Holdings Limited compare | −$12.5M |
| ALVO Alvotech compare | −$84.5M |
| TRLV Trulieve Cannabis Corp. compare | −$104.9M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$313.5M |
| PRGO Perrigo Company plc compare | −$1.2B |
| HCM HUTCHMED (China) Limited Sponsored ADR | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on HCM
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement